CML, Relapsed
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment (NCT03573596) | Amsterdam UMC, location VUmc | 2018-02-01 |
| Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments (NCT07517315) | Sun Pharma Advanced Research Company Limited |
Track CML, Relapsed automatically
Every clearance here is in the API, with alerts when new ones post.